Medeon Biodesign, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported sales was TWD 196.26 million compared to TWD 298.32 million a year ago. Net loss was TWD 1,204.62 million compared to TWD 433.76 million a year ago.

Basic loss per share from continuing operations was TWD 13.09 compared to TWD 4.71 a year ago. Diluted loss per share from continuing operations was TWD 13.09 compared to TWD 4.71 a year ago.